possible to avoid the occurrence of subsequent comorbidities caused by uncontrolled blood sugar. Dr. Li Hongyuan pointed out, "In recent years, the international concept of diabetes treatment has changed dramatically. It is no longer simply controlling blood sugar, but also protecting organs as soon as possible." The latest treatment guidelines published by the American Diabetes Association (ADA) suggest that physicians should assess the risk of comorbidities such as cardiovascular disease and kidney disease from the early stage of treatment of diabetic patients, while incretin (GLP-1 RA) and glycemic drugs (SGLT2 inhibitory) drug) is the drug recommended by the guidelines to give priority to use.
Not only does incretin stabilize blood sugar and old picture restoration body weight, research: it can also reduce the risk of cardio-renal comorbidities Among them, incretin has excellent performance in stabilizing blood sugar, weight loss, and alleviating comorbidities. But what exactly is incretin? Dr. Li Hongyuan explained that incretin is a protein hormone originally secreted by the human intestine, which can promote the secretion of insulin by pancreatic islet cells, and inhibit the secretion of glucagon to achieve the effect of regulating blood sugar.
At the same time, incretin can further act on the human stomach to inhibit gastric emptying (the faster the gastric emptying speed, the more likely to produce hunger); and promote the central nervous system of the brain to produce a feeling of satiety, which is suitable for fatter bodies (sugar fat). Diabetics) also have the benefit of assisting with weight control. And large-scale foreign research data shows that under the same blood sugar control, compared with other sugar control drugs, the use of incretin therapy can reduce the risk of cardiovascular disease by 14%, the occurrence of nephropathy by 21%, and the mortality rate by 12%. .